NCT05775432Recruiting
Prognosis of Heart Transplanted Patients With Heart Failure
Prognosis of Heart Transplanted Patients With Heart Failure (RE-START): a National Multi-center, Retrospective-prospective, Cohort Study
Source: ClinicalTrials.gov · Last updated 12 Jul 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Heart transplantation is the most effective treatment for end-stage heart failure, advanced cardiomyopathy, and complex congenital heart disease with severe heart failure or hypoxia. Several clinical studies have shown significant differences in the prognosis of heart transplantation patients with different etiologies, and post-transplantation complications are an important factor affecting patient survival, and there is still a lack of overall prognostic stratification and extensive clinical studies on risk factors after heart transplantation. Therefore, this study is intended to include patients who underwent heart transplantation for different etiologies of heart failure, collect clinical data and biological samples from patients, and use various techniques to deeply interpret the risk factors affecting the prognosis of heart transplantation patients and construct a prognostic prediction model to provide specific and individualized treatment ideas and theoretical basis for improving the survival rate of patients after heart transplantation.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 14 Feb 2023
- Start date
- 23 Apr 2023
- Primary completion date
- 31 Dec 2042
- Lead sponsor
- First Affiliated Hospital Xi'an Jiaotong University
- Diseases
- Heart failure
- NCT number
- NCT05775432
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 23 Apr 2023 to the primary completion date, 31 Dec 2042
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients refuse to sign informed consent form
Who the study is looking for
- Patients with end-stage heart failure presented to our hospital who are evaluated by clinicians and ethically approved for heart transplantation
- Individuals whose hearts are donated
Age in the registry: 3 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| First Affiliated Hospital of Xi'an Jiaotong University Coordinator of this site? Confirm its status | Xi'an | China | Recruiting |
Related publications
- PIEZO1 regulates smooth muscle cell plasticity by integrating mechanical stretch with glycolytic metabolism.Cardiovasc Res · 2026 · PMID 41846580
This page is information, not medical advice. Discuss any trial with your doctor.